Cadrenal Therapeutics Enters Material Definitive Agreement

TL;DR

Cadrenal Therapeutics signed a big deal on March 11th. Details to follow.

AI Summary

On March 11, 2024, Cadrenal Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal executive offices are located in Ponte Vedra, Florida.

Why It Matters

This filing indicates a significant new contract or partnership for Cadrenal Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not yet fully detailed in this initial filing.

Key Players & Entities

• Cadrenal Therapeutics, Inc. (company) — Registrant
• March 11, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 (address) — Principal executive offices
• 904-300-0701 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
• $5,143,730 — fined below) relates to the offering of $5,143,730 in shares of the Company's common stock

Filing Documents

• ea0201524-8k_cadrenal.htm (8-K) — 30KB
• ea020152401ex1-1_cadrenal.htm (EX-1.1) — 200KB
• 0001213900-24-021512.txt ( ) — 453KB
• cvkd-20240311.xsd (EX-101.SCH) — 3KB
• cvkd-20240311_lab.xml (EX-101.LAB) — 33KB
• cvkd-20240311_pre.xml (EX-101.PRE) — 22KB
• ea0201524-8k_cadrenal_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation, (the "Company"), entered into an At the Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent to sell shares of the Company's common stock, par value $0.001 per share, from time to time, through an "at the market offering" program pursuant to which Wainwright will act as sales agent. The prospectus supplement to the Registration Statement (defined below) relates to the offering of $5,143,730 in shares of the Company's common stock. The issuance and sale, if any, of common stock by the Company under the ATM Agreement is subject to the effectiveness of the Company's registration (the "Registration Statement"). The Company makes no assurances as to whether the Registration Statement will become effective or, if it does become effective, as to the continued effectiveness of the Registration Statement. Under the ATM Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, Wainwright may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, and applicable state and federal laws. The ATM Agreement may be terminated by the Company upon written notice to Wainwright, as specified in the ATM Agreement for any reason or by Wainwr

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 1.1 At the Market Offering Agreement by and between Cadrenal Therapeutics, Inc. and H.C. Wainwright & Co., LLC 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 11, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR